Your SlideShare is downloading. ×
0
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals

1,755

Published on

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent two families of bowel disorders with a common denominator of significant unmet medical need. The main unmet need in IBD is …

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent two families of bowel disorders with a common denominator of significant unmet medical need. The main unmet need in IBD is disease modifying therapies with greater efficacy in order to slow disease progression and maintain remission, particularly for severe patients. The development pipeline is bursting with potential candidates to treat IBD. In comparison, however, the IBS pipeline is relatively dry as drug developers struggle to unwind the complex pathology behind this disorder. The main unmet need in IBS is effective therapies indicated specifically to alleviate the symptoms of this syndrome.

New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals research finds that prescription pharmaceuticals indicated for IBD and IBS earned revenues of approximately $4.26 billion in 2011 and estimates this to reach $7.70 billion in 2017. The analysis finds that the growth is aided by an expansion of the market for biologicals and the introduction of efficacious new therapies.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,755
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
19
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals Bowel Disorders Market is Buoyant and Poised for Growth NBB6-52 November 2012
  • 2. ContentsSection Slide Numbers Executive Summary 14 Market Overview 20 • Definitions 21 • Overview of Inflammatory Bowel Disease 23 o Incidence and Prevalence of Inflammatory Bowel Disease 24 o Diagnosis of Inflammatory Bowel Disease 25 o Clinical Severity of Inflammatory Bowel Disease 27 o Assessment of Disease Activity in IBD Clinical Trials 29 o Anatomic Extent of Ulcerative Colitis 31 o Clinical Guidelines 33 • Overview of Irritable Bowel Syndrome 38 o Diagnosis of IBS 39 o Assessment of Disease Activity in IBS Clinical Trials 40 o Clinical Trial Design Guidance—IBS 41 o Clinical Guidelines—IBS 43 • Personalized Medicine in Bowel Disorders 44 • Key Questions This Study Will Answer 45 • Market Overview—Segmentation 46NBB6-52
  • 3. Contents (continued)Section Slide Numbers External Challenges: Drivers and Restraints 57 Forecasts and Trends 69 Demand Analysis 84 Market Share and Competitive Analysis 87 Inflammatory Bowel Disease Prescription Pharmaceuticals Segment 123 •5-ASA Subsegment Breakdown 127 •Corticosteroid Subsegment Breakdown 138 •TNF Inhibitor Subsegment Breakdown 149 •Non-TNF Biologicals Subsegment Breakdown 160 •Novel Orals Subsegment Breakdown 169 Irritable Bowel Syndrome Prescription Pharmaceuticals Segment 177 The Last Word (Conclusions and Implications) 188 Game-changing Strategies 193 Appendix 195NBB6-52
  • 4. Research TeamLead Analyst Contributing AnalystDeborah Toscano Jennifer BriceSenior Industry Analyst Global Program ManagerLife Sciences Life SciencesResearch Director Strategic Review Committee LeaderDaniel Ruppar Greg CaressiResearch Director Sr. Vice PresidentHealthcare HealthcareNBB6-52
  • 5. Executive Summary—CEO’s Perspective Growth opportunity in the IBD market lies in 1 introduction of improved products, whereas the IBS market is largely untapped. Convenience, efficacy, safety, and tolerability 2 are paramount to the success of new therapies. More drug therapies must be developed for 3 IBD patients who fail first line therapies. Gastrointestinal bowel disorders affect a 4 large population across a wide demographic. Strategies to optimize patient adherence to 5 therapy could greatly improve overall clinical outcomes and product success. Source: Frost & Sullivan analysis.NBB6-52
  • 6. Market Overview—Segmentation Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011 Total Bowel Disorders Prescription Pharmaceuticals Market IBS IBD IBS-C IBS-D CD* UC* Oral or Injectable Treatments Topical Treatments***Considered collectively in forecasts** Not evaluated in this research Source: Frost & Sullivan analysis. NBB6-52
  • 7. Market Overview—Segmentation (continued) Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011 Inflammatory Bowel Disease Prescription Pharmaceuticals Market CD UC Oral or Injectable Treatments Topical Treatments* 5-ASA Antibiotics* Corticosteroid Antimetabolite* Biologicals Novel Orals** ASA Corticosteroid TNFs Non-TNF Biologicals•Not covered in this research service** Investigational; none yet approved for IBD Source: Frost & Sullivan analysis. NBB6-52
  • 8. Market Overview—Segmentation (continued) Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Segmentation, U.S., 2011 Irritable Bowel Syndrome Prescription Pharmaceuticals Market IBS-C IBS-M* IBS-D 5-HT3 (serotonin) Chloride channel (ClC-2) activator (laxative) antagonist Guanylate cyclase type- C receptor agonist*Not covered in this research service due to lack of approved therapiesNote: Subsegmentation of the IBS market segment is not provided due to low level of commercial activity Source: Frost & Sullivan analysis. NBB6-52
  • 9. Market Overview—Segmentation (continued) Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 IBS-C Drugs, 5.5% IBS-D Drugs, 1.1% Corticosteroids, 8.6 % TNF inhibitors, 48.7% Biologicals, 49.5% 5-ASA, 35.3% Non-TNF biologicals, 0.8% Note: All figures are rounded. The base year is 2011. Source: Frost & Sullivan analysis.NBB6-52
  • 10. Drivers and Restraints Total Bowel Disorders Prescription Pharmaceuticals Market: Key Market Drivers and Restraints, U.S., 2012–2017 1–2 Years 3–4 Years 5–6 Years Substantial patient population with unmet need despite availability of numerous therapiesMarket Drivers Demand for more effective and convenient therapies is driving innovation Commercial advantage of potential for lifelong therapy, particularly if surgery is delayed or prevented Highly symptomatic diseases for which patients are motivated to seek treatment Accurate estimation of market size is difficult Market Restraints Poor adherence to therapy impedes optimal uptake High risk of failure late in the development process Lack of solid understanding of disease pathology Impact: High Medium Low Source: Frost & Sullivan analysis. NBB6-52
  • 11. Market Engineering MethodologyOne of Frost & Sullivan’s core deliverablesis its Market Engineering studies. Theyare based on our proprietary MarketEngineering Methodology. This approach,developed across the 50 years ofexperience assessing global markets,applies engineering rigor to the oftennebulous art of market forecasting andinterpretation.A detailed description of the methodologycan be found here. Source: Frost & Sullivan research.NBB6-52
  • 12. ContactBritni MyersHealthcare 210.477.8481 Britni.myers@frost.comNBB6-52

×